These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 35962033)

  • 1. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.
    Haynes BF; Wiehe K; Borrow P; Saunders KO; Korber B; Wagh K; McMichael AJ; Kelsoe G; Hahn BH; Alt F; Shaw GM
    Nat Rev Immunol; 2023 Mar; 23(3):142-158. PubMed ID: 35962033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
    Williams WB; Wiehe K; Saunders KO; Haynes BF
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.
    Wiehe K; Saunders KO; Stalls V; Cain DW; Venkatayogi S; Martin Beem JS; Berry M; Evangelous T; Henderson R; Hora B; Xia SM; Jiang C; Newman A; Bowman C; Lu X; Bryan ME; Bal J; Sanzone A; Chen H; Eaton A; Tomai MA; Fox CB; Tam YK; Barbosa C; Bonsignori M; Muramatsu H; Alam SM; Montefiori DC; Williams WB; Pardi N; Tian M; Weissman D; Alt FW; Acharya P; Haynes BF
    Cell Host Microbe; 2024 May; 32(5):693-709.e7. PubMed ID: 38670093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.
    Wiehe K; Bradley T; Meyerhoff RR; Hart C; Williams WB; Easterhoff D; Faison WJ; Kepler TB; Saunders KO; Alam SM; Bonsignori M; Haynes BF
    Cell Host Microbe; 2018 Jun; 23(6):759-765.e6. PubMed ID: 29861171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.
    Mu Z; Haynes BF; Cain DW
    Curr Opin Virol; 2021 Dec; 51():172-178. PubMed ID: 34742037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.
    Gao F; Bonsignori M; Liao HX; Kumar A; Xia SM; Lu X; Cai F; Hwang KK; Song H; Zhou T; Lynch RM; Alam SM; Moody MA; Ferrari G; Berrong M; Kelsoe G; Shaw GM; Hahn BH; Montefiori DC; Kamanga G; Cohen MS; Hraber P; Kwong PD; Korber BT; Mascola JR; Kepler TB; Haynes BF
    Cell; 2014 Jul; 158(3):481-91. PubMed ID: 25065977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
    Sliepen K; Sanders RW
    Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    Rao PG; Lambert GS; Upadhyay C
    J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.
    Bonsignori M; Liao HX; Gao F; Williams WB; Alam SM; Montefiori DC; Haynes BF
    Immunol Rev; 2017 Jan; 275(1):145-160. PubMed ID: 28133802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals.
    Kreer C; Lupo C; Ercanoglu MS; Gieselmann L; Spisak N; Grossbach J; Schlotz M; Schommers P; Gruell H; Dold L; Beyer A; Nourmohammad A; Mora T; Walczak AM; Klein F
    Nat Commun; 2023 Nov; 14(1):7137. PubMed ID: 37932288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host controls of HIV broadly neutralizing antibody development.
    Kelsoe G; Haynes BF
    Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
    Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
    Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
    Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.